Kahan A, Amor B, Menkès C J, Weber S, Guérin F, Degeorges M
Angiology. 1987 Apr;38(4):333-7. doi: 10.1177/000331978703800407.
The efficacy of the calcium-channel blocker nicardipine in the treatment of Raynaud's phenomenon was assessed in a prospective, double-blind, randomized, crossover trial in 20 patients. Each patient received nicardipine 20 mg or placebo three times a day for two weeks and then was crossed over for two weeks. Nicardipine significantly decreased the frequency and severity of Raynaud's phenomenon as compared with placebo. The authors conclude that nicardipine is effective in the treatment of Raynaud's phenomenon.
在一项针对20名患者的前瞻性、双盲、随机、交叉试验中，评估了钙通道阻滞剂尼卡地平治疗雷诺现象的疗效。每位患者每天服用3次20毫克尼卡地平或安慰剂，持续两周，然后交叉服用两周。与安慰剂相比，尼卡地平显著降低了雷诺现象的发作频率和严重程度。作者得出结论，尼卡地平对雷诺现象的治疗有效。
